Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-08-01

Clinical Trial Update: OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001 [Phase 2]

View source ↗

Summary

Phase 2 open-label study update for ANAVEX2-73 in Parkinson's disease with dementia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ANAVEX2-73 (blarcamesine)

Snippet

Sponsor: Anavex Life Sciences Corp. | Conditions: Parkinson Disease Dementia | Phase 2 | Status: COMPLETED